Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Clinical evidence

NCT03459079

52 evidence topics · 6 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
Eligibility criteria
Treatment
Study outcomes
Rationale for using intrahepatic triglyceride content by proton magnetic resonance spectroscopy as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline clinical and laboratory characteristics, FAS (published report)
CharacteristicPlacebo (n = 18)Lanifibranor (n = 20)
Age, years (mean ± SD)“58 ± 11”“61 ± 7”
Gender (% male/female)“28/72”“45/55”
White, n (%)“15 (83%)”“18 (90%)”
Weight, kg (mean ± SD)“99 ± 20”“96 ± 14”
Body mass index, kg/m2 (mean ± SD)“34.3 ± 6.2”“33.8 ± 5.1”
Fasting plasma glucose, mg/dl (mean ± SD)“122 ± 22”“130 ± 26”
HbA1c, % (mean ± SD)“7.0 ± 0.8”“6.8 ± 0.5”
Fasting plasma insulin, μU/ml (mean ± SD)“18.2 ± 12.7”“16.4 ± 8.6”
Triglycerides, mg/dl (mean ± SD)“196 ± 101”“175 ± 95”
HDL-C, mg/dl (mean ± SD)“43 ± 12”“42 ± 9”
Alanine aminotransferase, U/L (mean ± SD)“35 ± 27”“37 ± 20”
Aspartate aminotransferase, U/L (mean ± SD)“31 ± 19”“31 ± 14”
HOMA-IR (mean ± SD)“5.4 ± 3.4”“5.6 ± 3.2”
Adiponectin, μg/ml (mean ± SD)“5.0 ± 3.7”“4.5 ± 2.8”
Intrahepatic triglyceride content, % (mean ± SD)“18 ± 7”“21 ± 7”
Liver stiffness by MRE, kPa (mean ± SD)“2.5 ± 1.1”“2.8 ± 0.8”
Efficacy results
IHTG endpoints at week 24 (registry)
OutcomeLanifibranor (n = 20)Placebo (n = 18)
Absolute change in IHTG, LS mean (95% CI)“-8.7 (-11.3 to -6.0)”“-3.0 (-5.9 to -0.2)”
IHTG decrease of ≥30%, % of participants (95% CI)“65 (41 to 85)”“22 (6 to 48)”
NAFLD resolution (IHTG ≤5.5%), % of participants (95% CI)“25 (9 to 49)”“0 (0 to 19)”
Secondary metabolic endpoints at week 24, FAS adjusted LS means (published report)
Endpoint, FASLanifibranor, adjusted LS mean [95% CI]Placebo, adjusted LS mean [95% CI]Adjusted LS mean difference [95% CI]p value
Fasting hepatic glucose production, relative change (%)“-8 [-13; -4]”“4 [-1; 9]”“-13 [-20; -6]”“<0.001”
Hepatic IR index, relative change (%)“-26 [-37; -14]”“-7 [-19; 4]”“-18 [-34; -2]”“0.04”
Insulin-stimulated muscle glucose disposal, relative change (%)“30 [13; 46]”“0 [-17; 18]”“29 [5; 54]”“0.02”
Fasting plasma insulin, absolute change (μU/ml)“-3.1 [-5.5; -0.8]”“-0.0 [-2.5; 2.5]”“-3.1 [-6.5; 0.3]”“0.07”
Fasting plasma glucose, absolute change (mg/dl)“-17.2 [-27.4; -7.0]”“2.4 [-8.4; 13.2]”“-19.6 [-34.5; -4.7]”“0.01”
HOMA-IR, absolute change“-1.6 [-2.5; -0.7]”“-0.1 [-1.1; 0.8]”“-1.5 [-2.8; -0.2]”“0.03”
Adipo-IR, absolute change“-2.7 [-4.3; -1.2]”“-0.7 [-2.4; 0.9]”“-2.0 [-4.2; 0.3]”“0.08”
HbA1c, absolute change (%)“-0.7 [-1.0; -0.5]”“-0.1 [-0.3; 0.2]”“-0.6 [-1.0; -0.5]”“<0.001”
HDL-C, absolute change (mg/dl)“7.6 [4.4; 10.7]”“0.9 [-2.4; 4.3]”“6.6 [2.0; 11.3]”“0.006”
Adiponectin, fold change“2.4 [2.0; 2.7]”“1.0 [0.6; 1.4]”“1.4 [0.9; 1.9]”“<0.001”
Liver stiffness by transient elastography and MRE and plasma cytokeratin-18 at week 24 (registry)
OutcomeLanifibranorPlacebo
Liver stiffness by vibration controlled transient elastography, absolute change in kPa, LS mean (95% CI); n = 20 and 18“-1.49 (-2.66 to -0.31)”“-0.34 (-1.57 to 0.9)”
Liver stiffness by MRE, change in kPa, LS mean (95% CI); n = 18 and 18“0.23 (0.03 to 0.42)”“-0.06 (-0.25 to 0.13)”
Plasma cytokeratin 18, absolute change in IU/L, mean (SD); n = 20 and 18“-130.71(164.28)”“-70.21(230.39)”
Topline results, FAS and completers (company release, June 2023)
Completers, change from baseline to week 24Placebo (n=14)Lanifibranor 800 mg (n=14)
Absolute change in HbA1c, %“-0.2%”“-0.9”
Absolute change in fasting plasma insulin, μU/ml“-1.0”“-6.7”
Absolute change in hepatic insulin resistance index“-9.5”“-30.1”
Absolute change in basal endogenous glucose production (mg/kgLBM/min)“0.1”“-0.5”
Absolute change in muscle insulin-stimulated glucose disposal (mg/kg LBM/min)“-0.2”“+2.2”
Absolute change in HDL-C, mg/dl“-0.3”“6.3”
Absolute change in adiponectin, μg/mL“-0.2”“7.5”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by group (published report)
Event, n (%)Placebo (n = 18)Lanifibranor (n = 20)
Patients with TEAEs“17 (94%)”“18 (90%)”
Patients with severe TEAEs“0 (0%)”“1 (5%)”
Patients with serious adverse events“0 (0%)”“1 (5)”
TEAEs leading to drug discontinuation“2 (11%)”“4 (20%)”
Drug-related TEAE leading to discontinuation“2 (11%)”“3 (15%)”
Diarrhea“3 (17%)”“5 (25%)”
Elevated lipase level“3 (17%)”“5 (25%)”
Anemia“2 (11%)”“4 (20%)”
Leukopenia“1 (6%)”“3 (15%)”
Headache“1 (6%)”“3 (15%)”
Arthralgia“3 (17%)”“0 (0%)”
Oedema“0 (0%)”“1 (5%)”
Hypoglycemia“0 (0%)”“1 (5%)”
Decrease in eGFR“2 (11%)”“1 (5%)”
Mortality, serious adverse events, and selected other adverse events over 28 weeks (registry)
Event, affected / at risk (%)LanifibranorPlacebo
All-cause mortality“0/20 (0.00%)”“0/18 (0.00%)”
Serious adverse events, total“1/20 (5.00%)”“0/18 (0.00%)”
Other (not including serious) adverse events, total“18/20 (90.00%)”“17/18 (94.44%)”
Anaemia“4/20 (20.00%)”“2/18 (11.11%)”
Diarrhoea“5/19 (26.32%)”“3/18 (16.67%)”
Elevated lipase level“5/20 (25.00%)”“3/18 (16.67%)”
Edema“1/20 (5.00%)”“0/18 (0.00%)”
Study limitations
Summary: design, sample size, and enrolled population
  • The trial was single-center (Gainesville, Florida) and investigator-initiated, with financial support from Inventiva; the Inventiva research and development team had access to the database lock and assisted in the final analysis.
  • The planned number of participants was reduced during the trial on the basis of NATIVE steatosis results, to 15 per group completing treatment (power 0.80) and 33 to 34 randomized. A total of 38 participants were randomized (20 lanifibranor, 18 placebo), and 28 completed 24 weeks (14 [70%] and 14 [78%]). The registry states that the COVID epidemic greatly impacted recruitment and promoted dropout. The registry enrollment of 128 counts all enrolled participants, of whom 38 were randomized and 10 were healthy controls.
  • The registry gave an estimated recruitment period of about 9 months; randomization took place between August 2018 and April 2023.
  • The authors state that the study did not seek to recruit patients with MASH (fibrosis stage ≥F2) or to assess the role of improving insulin resistance on liver histology, for which the study was “not statistically powered”. The protocol states that the liver fat thresholds are assumed to correlate with histological changes based on the investigator's experience.
  • The discussion of the published report describes mild hyperglycemia with a mean baseline HbA1c of 7.2%; the baseline table gives 7.0 ± 0.8% with placebo and 6.8 ± 0.5% with lanifibranor. The male/female percentages at baseline were 28/72 with placebo and 45/55 with lanifibranor.
Summary: missing-data handling, multiplicity, and figures that differ by source
  • For missing week 24 IHTG data, the primary analysis used the baseline value under stated conditions; missing categorical data were imputed as failure, and missing data for the secondary metabolic endpoints were imputed by last observation carried forward.
  • The protocol defined no plan to control multiplicity for secondary or exploratory endpoints, which are considered exploratory.
  • The absolute change in IHTG differs by source. The 2023 congress poster reports -10.1% with lanifibranor versus -1.4% with placebo in the FAS and -12.4% versus -2.4% in completers; the published report gives -8.7% versus -3.0% (FAS) and -10.8% versus -4.0% (completers), and the registry gives -8.7 and -3.0. Both the poster and the published report give LS mean differences of -5.6% (FAS) and -6.9% (completers).